Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketorolac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 1.00 |
| ▸ | CDC42 | P60953 | 3/20 | 1.00 |
| ▸ | RAC1 | P63000 | 3/20 | 1.00 |
| ▸ | PAK1 | Q13153 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | CA4 | P22748 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 4/20 | 0.59 |
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketorolac SCHEMBL4103 | 1.00 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL14891 | 1.00 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL23466702 | 1.00 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL28472361 | 0.98 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL20553125 | 0.98 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL28480507 | 0.98 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL28826490 | 0.98 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL15661224 | 0.98 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL18797655 | 0.98 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL5301763 | 0.98 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 57558 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-121588023-B | Soluble microneedle | ZHONGKE WEIZHEN (BEIJING) TECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-20260130928-A1 | COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2026-05-14 | — | — | US | claimed |
| US-20260132191-A1 | METHODS FOR MODULATING ACTIVITY OF IL-18 FOR TREATMENT OF CD4+ T CELL MEDIATED AUTOIMMUNITY AND IMMUNOPATHOLOGY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-05-14 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | claimed |
| US-12605432-B2 | Combinations for antigen based therapy | DIAMYD MEDICAL AB (SE) | 2026-04-21 | — | — | US | claimed |
| WO-1991013609-A1 | USE OF KETOROLAC FOR TREATMENT OF PERIODONTAL DISEASE | THE PROCTER & GAMBLE COMPANY (US) | 1991-09-19 | — | — | WO | claimed |
| EP-0445255-A1 | TREATMENT OF CONDITIONS AND DISEASE. | NORPHARMCO INC (CA) | 1991-09-11 | — | — | EP | claimed |
| CN-1051503-A | Disease and treatment of diseases | NORPHARMCO INC (CA) | 1991-05-22 | — | — | CN | claimed |
| EP-0422681-A1 | Collagen containing ophthalmic formulation | SYNTEX (U.S.A.) INC. (US) | 1991-04-17 | — | — | EP | claimed |
| WO-1991004058-A2 | TREATMENT OF CONDITIONS AND DISEASE | NORPHARMCO INC. (CA) | 1991-04-04 | — | — | WO | claimed |
| EP-0390071-A1 | Preservative system for ophthalmic formulations | SYNTEX (U.S.A.) INC. (US) | 1990-10-03 | — | — | EP | claimed |
| US-4919939-A | Periodontal disease treatment system | PHARMETRIX CORPORATION (US) | 1990-04-24 | — | — | US | claimed |
| EP-0306984-A1 | Preservative system for ophtalmic formulations | SYNTEX (U.S.A.) INC. (US) | 1989-03-15 | — | — | EP | claimed |
| EP-0289262-A2 | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1988-11-02 | — | — | EP | claimed |
| EP-0251680-A2 | Controlled release bioerodible drug delivery system | IOLAB, INC (US) | 1988-01-07 | — | — | EP | claimed |